Surgery Partners, Inc.

From time to time, certain of our executive officers and directors have, and we expect they will in the future, enter into, amend and terminate written trading arrangements pursuant to Rule 10b5-1 of the Securities and Exchange Act of 1934 or otherwise. During the three months ended December 31, 2025, none of the Company's directors or officers adopted orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).

Board Member Appointment

On February 26, 2026, the Board of Directors of the Company appointed Lloyd Dean as a Class I director to fill the vacant directorship. As a Class I director, Mr. Dean’s term expires at the 2028 annual meeting of stockholders. The Board has determined that Mr. Dean is independent in accordance with Nasdaq listing standards.

The Board has not appointed Mr. Dean to any committees of the Board, and it is unknown which committees of the Board Mr. Dean will serve on at this time.

Mr. Dean’s compensation will be materially consistent with other non-employee directors of the Company, as described in the definitive proxy statement for the Company’s 2025 annual meeting of stockholders, filed with the Securities and Exchange Commission on April 24, 2025. Additionally, Mr. Dean entered into the Company’s standard form of indemnification agreement.